NIH-funded research R01 grant

Developing new vaccines to combat antimicrobial resistant infections

Official title: Deciphering the amine/acetylation code of PNAG through comprehensive libraries of synthetic oligosaccharides for effective anti-microbial vaccines

Funded at Michigan State University · NIH-11049361 · Data updated 2026-11-12

This study is working on new vaccines to help protect people from infections caused by germs that don't respond to regular antibiotics, by focusing on a specific part of these germs that can help boost the immune system's response.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionMichigan State University
NIH-funded
Lab location1 site (East Lansing, United States)
Project startNovember 12, 2024
Project endOctober 31, 2029
Funding year2025
Award (this year)$837,644
NIH project number1R01AI182419-01A1
Project IDNIH-11049361 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals at risk of infections caused by antimicrobial resistant bacteria.

Less likely to help

Patients who are not at risk for infections or those who do not respond to vaccines may not benefit from this research.

What this research studies

This research focuses on creating innovative vaccines to prevent infections caused by antimicrobial resistant microbes. It investigates a specific target called Poly-β-(1−6)-N-acetylglucosamine (PNAG), which is found on the surface of many harmful pathogens. The team will synthesize a variety of PNAG structures with different chemical modifications to understand how these variations affect the immune response. By linking these PNAG structures to a strong immunogenic carrier, the research aims to enhance the effectiveness of the vaccines in generating protective immunity.

Why it matters

Potential benefit: If successful, this research could lead to the development of effective vaccines that protect against infections from antibiotic-resistant pathogens.

How similar studies have gone: Other research has shown promise in developing vaccines targeting similar virulence factors, indicating potential success for this approach.

Where this research is happening

  • Michigan State University
    East Lansing, United States
    Active

Researchers

  • Principal investigator: Huang, Xuefei — Michigan State University
  • Study coordinator: Huang, Xuefei

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.